This compound is a pharmaceutical intermediate specifically used in the synthesis of filgotinib. It features a triazolopyridine core with a bromomethylphenyl substituent and a cyclopropanecarboxamide group, reflecting its role as a building block in pharmaceutical manufacturing.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 1206163-59-8
N-(5-(4-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
pharmaceutical intermediate
(5-Bromo-3-(trifluoromethyl)pyridin-2-yl)methanol
pharmaceutical intermediate
5-Deamino-5-oxo Amiloride Hydrochloride
pharmaceutical impurity reference standard
(2S,3S)-2-Amino-3-methyl-3-sulfino-4-(1H-1,2,3-triazol-1-yl)butyric acid
Tazobactam metabolite M1 reference standard
(5R,6S)-Allyl 6-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
synthetic beta-lactam intermediate
N-(5-(4-formylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
Pharmaceutical intermediate for Filgotinib synthesis
N-[5-[4-(bromomethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
NEOZIFRQXFFBFZ-UHFFFAOYSA-N
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CBr
—